Detecting silent cerebral infarcts on magnetic resonance images (MRIs) in children with sickle cell anemia is challenging, yet reproducibility of readings has not been examined in this population. We evaluated consensus rating, inter-, and intra-grader agreement associated with detecting silent cerebral infarct on screening MRI in the Silent Infarct Transfusion Trial. Three neuroradiologists provided consensus decisions for 1073 MRIs. A random sample of 53 scans was reanalyzed in blinded fashion. Agreement between first and second consensus ratings was substantial (k ¼ 0.70, P < .0001), as was overall intergrader agreement (k ¼ 0.76, P < .0001). In the test-retest sample, intragrader agreement ranged from k of 0.57 to 0.76. Consensus decisions were more concordant when MRIs contained more than one larger lesions. Routine use of MRI to screen for silent cerebral infarcts in the research setting is reproducible in sickle cell anemia and agreement among neuroradiologists is sufficient.
Cerebrovascular disease among individuals with sickle cell anemia has a spectrum of presentation ranging from acute, neurologically devastating infarction to clinically silent cerebral infarction. First-time clinically overt strokes, which are associated with focal neurologic dysfunction, occur in up to 11% of unscreened individuals with sickle cell anemia by age 20 years. 1 Overt strokes in children with sickle cell anemia typically occur in the distribution of large vessels, such as the distal internal carotid or middle cerebral arteries. In contrast, silent cerebral infarcts are not associated with acute neurologic symptoms and are distinguished from overt strokes by smaller lesions frequently in the deep cortical white matter. 2, 3 Although silent cerebral infarcts have been noted in 27% of children with sickle cell anemia younger than age 6 years, 4 no consensus exists regarding their treatment.
Despite the recognition that silent cerebral infarcts may be progressive 3 and associated with an increased incidence rate of overt strokes, 5 cognitive deficits, 6, 7 and poor academic attainment, 8 routine screening to detect silent cerebral infarcts in children with sickle cell anemia has generally been limited to pediatric hematology centers with a clinical and research focus on acquired brain injury in this population. The diagnosis of silent cerebral infarcts may also be difficult given their smaller size when compared to overt strokes, coupled with the lack of clinical symptoms and the requirement for specific neuroradiology expertise available at limited larger pediatric centers.
Silent cerebral infarcts have previously been defined as foci of abnormally elevated T2-weighted signal intensity on magnetic resonance imaging (MRI) that measure at least 3 mm in one or more axes and are seen in 2 imaging planes. 9 The determination of silent cerebral infarcts requires that focal neurologic symptoms or signs that might correlate with lesion location be absent on history and physical examination. 10, 11 Few studies have examined reader agreement in the measurement of silent cerebral infarcts or white matter lesions. [12] [13] [14] Based on lesion size alone, inter-and intra-observer agreement may be lower in individuals with silent cerebral infarcts when compared to overt strokes. 15, 16 To our knowledge, no study has evaluated intra-and interobserver agreement related to the detection of silent cerebral infarcts in sickle cell anemia or in children even though the clinical implications of such findings are considerable.
The Silent Infarct Transfusion Trial is a multicenter, randomized clinical trial to evaluate the safety and benefit of chronic transfusion therapy in children with sickle cell anemia and silent cerebral infarcts. Study eligibility depends on accurate determination of the presence of silent cerebral infarcts on screening MRI. On the basis of clinical experience, the trial leadership assumed a priori that the detection of silent cerebral infarcts on MRI would be associated with some degree of variability. As such, the trial provides an opportunity to examine agreement among 3 neuroradiologists, who comprise the neuroradiology adjudication panel for the trial, to independently assess the presence or absence of silent cerebral infarcts on MRI over time.
We tested the hypothesis that a high level of agreement would be achieved among neuroradiologists faced with detecting silent cerebral infarcts on screening MRI in children with sickle cell anemia enrolled in the Silent Infarct Transfusion Trial. The primary objective of this study is to describe the consistency of the consensus decisions made by the neuroradiology panel of the Silent Infarct Transfusion Trial when screening MRIs were reinserted into their work queue without their knowledge. A secondary objective is to determine inter-and intra-rater agreement related to the detection of silent cerebral infarcts on screening MRI obtained at study entry and on reinserted studies, respectively. The last objective is to examine whether number, size, and location of silent cerebral infarcts affected consensus decisions on MRI adjudication.
Methods
The Silent Infarct Transfusion Trial relied on a centralized, digital workflow in which all MRIs are electronically transmitted from participating institutions for central review. 9 Three neuroradiologists at separate institutions comprised the neuroradiology adjudication panel for this trial and performed blinded assessments of each MRI. Patient and study identifiers were stripped prior to insertion of each assessment MRI into a digital queue for reading. Before the trial began, each of the 3 neuroradiologists underwent web-based training using a standard set of MRIs developed to instruct them on the detection of silent cerebral infarcts (see supplemental online figures at http://jcn.sagepub.com/ supplemental). Together, these neuroradiologists established a working differential diagnosis for increased T2-weighted signal intensity on MRI specifically for the trial.
Silent Infarct Transfusion Trial Screening MRIs
Each neuroradiologist independently established whether or not the technical quality of each screening MRI was sufficient for determination of the presence of a silent cerebral infarct. The presence or absence of a silent cerebral infarct was determined by independent responses (''yes,'' ''no,'' or ''indeterminate'') by each neuroradiologist to the question ''Based on the results of the MRI, the patient has at least one infarct-like lesion.'' Consensus decisions were concordant if all 3 neuroradiologists reached the same response. Disagreements were resolved by conference call to render a consensus decision (Figures 1 and 2 ). For each screening MRI that contained a silent cerebral infarct, these lesion characteristics were recorded: total lesion number, location of each lesion and volumetric size of each lesion. Each lesion was classified as located in either the right or left parietal, occipital, temporal, or frontal lobe of the brain. Lesion location and size were evaluated only on studies with single lesions (n ¼ 88) to minimize confusion regarding which lesion or lesions contributed to a neuroradiologist's primary response.
Test-Retest Agreement Sample
A total of 53 MRIs for evaluating test-retest agreement were selected from a proportionate random sample of screening MRIs determined to be either positive or negative for the presence of a silent cerebral infarct by consensus. These scans constituted the quality control test-retest sample used to assess the consistency of the neuroradiology consensus decisions. Indeterminate scans were excluded from the testretest sample because they comprised fewer than 5% of the consensus decisions. Proxy clinic and patient IDs were assigned to the test-retest sample of screening MRIs, which were reanalyzed independently by the 3 neuroradiologists. Neuroradiologists were unaware of the reinsertion of the quality assurance MRIs and were masked to the initial consensus rating of each screening MRI in the test-retest sample.
Statistical Considerations
Simple kappa (k) statistic was calculated to reflect agreement between the first and second consensus decision by the neuroradiology panel.
To calculate intergrader agreement, k statistics for ordinal data were calculated using the preconsensus decisions of the 3 neuroradiologists, also referred to as graders. This overall intergrader k statistic was computed using the SAS Macro %MAGREE, and intraclass correlations were computed using the SAS Macro %INTRACC. To assess intragrader agreement between the first and second reviews of the same MRI study in the test-retest sample, weighted k statistics were calculated for each grader. Weighted k statistics were also computed for the agreement between each grader's ratings and the consensus decisions for both the entire screening set of MRIs and the test-retest sample. Jonckheere-Terpstra and Cochran-Armitage tests were used to test trends in k statistics and positive MRI studies, respectively, over time. In accordance with previously accepted criteria by Landis and Koch, k values greater than 0.4 indicate ''moderate agreement,'' values greater than 0.6 indicate ''substantial agreement'' and values greater than 0.8 indicate ''excellent'' or ''near perfect agreement.'' 17 Finally, logistic regression modeling and chi-square/Fisher exact test were used to assess the relationship of lesion and subject characteristics, both continuous and categorical, to consensus decisions. Kruskal-Wallis test was performed to examine the association between lesion size and consensus decisions for single lesions. All statistical analyses were performed using SAS, version 9.3 (SAS Institute Inc, Cary, NC).
Results

Demographic Characteristics of Screening and Test-Retest Samples
Of the total 1091 screening MRIs subjected to quality control review, 1073 scans were judged to be gradable and included in this study. A subset of 53 scans, which represented the test-retest sample, was randomly selected from the 1073 screening MRIs and reassessed by all 3 neuroradiologists. For this test-retest sample, average time between the initial scan and its reinsertion into the work queue was 3 years, with a range of 5 months to 5 years. The age of the subjects whose MRIs were included was similar in the screening versus testretest samples (9.1 + 2.5 vs 9.0 + 2.4 years) ( Table 1 ). The proportion of males included in the 2 samples was also similar (50.9% vs 54.7%). In both groups, the majority of subjects were of African descent and had hemoglobin SS as the primary genotype. Almost all of the MRIs in the screening and test-retest samples were obtained at 1.5 Tesla.
Consensus Agreement for Test-Retest MRI Sample
The overall agreement between the first consensus and second consensus ratings in the test-retest subset of screening MRIs was substantial (k ¼ 0.70, 95% confidence interval ¼ 0.51, 0.90, P < .0001). A total of 8 MRIs in this sample had discordant consensus ratings between the first and second reviews. Of these, 6 MRI consensus ratings went from ''no'' on the first review to ''yes'' on the second review, and 2 ratings went from ''yes'' to ''no.'' The demographic characteristics of the subjects and scans in this discordant group were similar to that of the screening and test-retest samples. 
Intergrader Agreement for All Screening MRIs
The overall individual agreement among the 3 neuroradiologists in determining if a silent cerebral infarct was present or absent on the 1073 screening MRIs was substantial (k ¼ 0.75, P < .0001). Discordant ratings were observed among the 3 neuroradiologists for only 24 (2.2%) out of all screening MRIs. Agreement was strongest for the ''yes'' rating category (k ¼ 0.80, P < .0001). Substantial intergrader agreement among the 3 graders was also supported by a calculated intraclass correlation Shrout-Fleiss reliability single score of 0.80.
Intragrader Agreement for Test-Retest MRI Sample
MRIs in the test-retest sample were regraded by all 3 neuroradiologists. A weighted k statistic for intragrader agreement between the first and second review was calculated for each Table 2) . For grader 1, the number of ''no'' ratings on the first review that changed to ''yes'' on the second review was 9 of 32 (28.1%), and the number of ''yes'' ratings that changed to ''no'' was 2 of 19 (10.5%). The high percentage of changes in ratings explained why intragrader agreement for grader 1 was lower than that observed for the other 2 graders. We found that 10/53 (18.9%) reinserted MRIs contributed to discordant ratings for at least 2 graders. No MRIs resulted in discordant ratings for all 3 graders.
Grader-Consensus Agreement Over Time
Overall, the agreement between individual ratings and consensus ratings for screening MRIs was excellent for all 3 neuroradiologists, with weighted k statistics ranging from 0.87 for Grader 2 to 0.91 for Grader 3 ( 
Factors Affecting Consensus Decisions
For screening MRIs with evidence for silent cerebral infarct, higher lesion number was significantly associated with greater concordance on consensus decisions (odds ratio ¼ 2.13, 95% confidence interval ¼ 1.51, 3.00, P < .0001). On MRIs with single lesions, lesions on average were greater in size for studies in which consensus decisions were concordant versus discordant (153.6 vs 93.6 mm 3 , P ¼ .055), although this finding did not reach statistical significance. Neither lesion location nor subject characteristics such as age or gender significantly influenced whether consensus decisions were concordant or discordant on MRIs with a single lesion (data not shown).
Discussion
Increasingly, silent cerebral infarcts are recognized as a prevalent and progressive cerebrovascular complication in children with sickle cell anemia, 18 and cognitive morbidity 7 but they may be challenging to detect on routine screening by MRI. This report represents the first to demonstrate that consensus detection of silent cerebral infarcts on MRIs such as those obtained in the Silent Infarct Transfusion Trial is reproducible in children with sickle cell anemia. Although detecting silent cerebral infarcts is clinically important, the routine use of MRI as a reliable tool for screening children with sickle cell anemia for silent cerebral infarcts has not been established. The overall intergrader as well as intragrader agreement in our study confirms the feasibility of detecting silent cerebral infarcts on MRIs. Further, we show that the evaluation of silent cerebral infarcts also remains consistent over time. A learning effect was evident in 2 of the 3 neuroradiologists, for whom improvements in individual grader versus consensus agreement were observed over time. Finally, we demonstrate that lesion number and size affect ability to detect silent cerebral infarcts on screening MRI in this population. Our assessment of the reproducibility associated with detecting silent cerebral infarcts on screening MRI in the Silent Infarct Transfusion Trial was rigorous for several reasons. A centralized, digital workflow allowed for the electronic transmission and insertion of MRIs stripped of patient identifiers to ensure blinded, independent assessments by each grader. 9 All 3 neuroradiologists underwent standardized training in the recognition of silent cerebral infarcts, and the procedures for evaluating the presence or absence of lesions, including a working definition of silent cerebral infarcts and their differential diagnosis, were outlined prior to the start of the study. Discrepancies in grader ratings for any MRI were subjected to adjudication and a consensus decision reached. MRIs that comprised the test-retest sample were reinserted into the digital workflow in a masked fashion so that the neuroradiologists were unaware of which MRIs were research and required a decision for eligibility and which were quality control scans, also ensuring that intragrader agreement would be evaluated without bias. There was low agreement between grader 1's first and second reviews of the same MRIs because grader 1 was more likely to find new lesions upon repeat review of the reinserted scans. This may reflect learned behavior or an improvement in detection due to the adjudication process. Overall, a learned behavior associated with improved detection of silent cerebral infarcts was also reflected in the consensus agreement for the test-retest sample as well as in grader-consensus agreement over time. Although there may be concern this learned behavior might result in bias toward more positive findings at the end of the Silent Infarct Transfusion trial, there in fact was a stable trend, rather than an increase, in the proportion of positive MRIs over time.
Differences in patient characteristics, measurement techniques, rating scales, agreement testing approach, and statistical methodology make it difficult to compare our results with that of other studies that have examined observer agreement in detecting white matter lesions. [12] [13] [14] 19 Subjects in previously published studies comprise mostly older individuals from large cohort studies at high risk for cerebrovascular disease. The pathophysiologic processes that underlie development of silent cerebral infarcts in sickle cell anemia versus deep white matter changes or lacunar infarcts in the general adult population are also potentially different. Nonetheless, intergrader agreement in our report was comparable to that described in the Kapeller et al study, 13 in which intergrader agreement ranged from 0.599 to 0.781 for baseline MRIs, and in the Wardlaw et al study, 14 in which intergrader agreement ranged from 0.720 to 0.890. Intragrader agreement in our study was superior to that observed in the De Schryver et al study, 12 in which investigators evaluated 126 scans twice 1 month apart for the presence of white matter lesions (k ¼ 0.580). With the exception of lesion number, the influence of other lesion characteristics on grader consensus was not significant. Though no prior studies have examined the relationship between lesion number and detection on MRI, we anticipated there would be greater agreement when more than 1 lesion was present.
Several limitations exist in this study. One is the relatively small size of our test-retest sample; however, our sample size was comparable to that of other similar studies published. The even smaller number of discordant ratings in the test-retest sample made it challenging to explore scan or subject characteristics that might have contributed to changes in ratings on a consensus or individual level. Possibly, our 3 neuroradiologists were not entirely unaware of the reinsertion of the MRIs used for the test-retest sample, which may have affected their performance during the second review. However, the neuroradiologists would not have known which MRIs were new and which were quality control studies given the blinding procedure used. Finally, the design of the Silent Infarct Transfusion trial and the neuroradiology adjudication process did not allow us to examine specific factors that might have affected individual grader test-retest reliability. We did not examine the relationship between lesion characteristics and inter-or intragrader agreement because all 3 neuroradiologists did not individually record lesion number or perform volumetric measurements. For this reason, the reproducibility of detecting smaller, single lesions, which was associated with lower concordance on consensus ratings, is not known for individual graders.
In summary, inter-and intragrader agreement among neuroradiologists is substantial and sufficient for detecting silent cerebral infarcts in children with sickle cell anemia. Our experience may not necessarily be extrapolated to other centers given the expertise of our neuroradiologists and the scientific rigor with which screening occurred in the Silent Infarct Transfusion Trial. Nonetheless, these results provide support for using MRI as a reliable tool in screening children with sickle cell anemia for silent cerebral infarcts in the research setting and have important implications for the interpretation of results. Proper training of neuroradiologists and standardization of imaging protocols and operational definitions are necessary to ensure accuracy and reliability in identifying silent cerebral infarcts by MRI, especially in the clinical setting. By adopting this approach, the use of MRI can and should be considered to improve detection of silent cerebral infarcts, a prevalent morbid and progressive condition in this population. 18 
